Elisa detection of salivary levels of cd44sol as a diagnostic test for laryngeal carcinomas

Journal of Cancer Science and Therapy

Volumn 4, Issue 10, 2012, Pages 330-334

  Allegra, Eugenia ^a   Trapasso, Serena ^a   Sacco, Antonella ^a   Aragona, Teodoro ^a   Belfiore, Antonino ^a   Garozzo, Aldo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

ELISA; Head and neck squamous cell carcinoma; Saliva; Screening; Soluble CD44

Indexed keywords

HERMES ANTIGEN; PROTEIN; SOLUBLE FRACTION OF THE CD44 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LARYNGEAL BIOPSY; LARYNX CANCER; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SALIVA ANALYSIS; SALIVA LEVEL; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 84869070406     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000163     Document Type: Article

References (37)

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
2. Liu J, Duan Y (2012) Saliva: A potential media for disease diagnostics and monitoring. Oral Oncol 48: 569-577.
3. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002) CD44 in cancer. Crit Rev Clin Lab Sci 39: 527-579.
4. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, et al. (1989) CD44 contributes to T cell activation. J Immunol 143: 798-801.
5. Toyama-Sorimachi N, Miyasaka M (1994) A sulfated proteoglycan as a novel ligand for CD44. J Dermatol 21: 795-801.
6. Peterson RM, Yu Q, Stamenkovic I, Toole BP (2000) Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol 156: 2159-2167.
7. Mayer S, Zur Hausen A, Watermann DO, Stamm S, Jäger M, et al. (2008) Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol 134: 1229-1235.
8. Masson D, Denis MG, Denis M, Blanchard D, Loirat MJ, et al. (1999) Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Br J Cancer 80: 1995-2000.
9. Van Hal NL, Van Dongen GA, Ten Brink CB, Heider KH, Rech-Weichselbraun I, et al. (1999) Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res 5: 3534-3541.
10. Franzmann EJ, Reategui EP, Carraway KL, Hamilton KL, Weed DT, et al. (2005) Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev 14: 735-739.
11. Koukourakis MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E (2012) Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer 106: 846-853.
12. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-777.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
14. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
15. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
16. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104: 10158-10163.
17. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
18. Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827-4833.
19. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104: 973-978.
20. Brandwein-Gensler M, Smith RV (2010) Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system. Head Neck Pathol 4: 53-61.
21. Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM (2007) Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 16: 1348-1355.
22. Franzmann EJ, Reategui EP, Pereira LH, Pedroso F, Joseph D, et al. (2012) Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck 34: 687-695.
23. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY (2009) CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 119: 1518-1530.
24. Rajarajan A, Stokes A, Bloor BK, Ceder R, Desai H, et al. (2012) CD44 expression in oro-pharyngeal carcinoma tissues and cell lines. PLoS One 7: e28776.
25. Lindquist D, Ahrlund-Richter A, Tarján M, Tot T, Dalianis T, et al. (2012) Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res 32: 153-161.
26. Kokko LL, Hurme S, Maula SM, Alanen K, Grénman R, et al. (2011) Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 47: 510-516.
27. Yüce I, Bayram A, Caǧli S, Canöz O, Bayram S, et al. (2011) The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol 32: 141-146.
28. Uwa N, Kataoka TR, Torii I, Sato A, Nishigami T, et al. (2011) CD44 expression is related to poor prognosis of hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 131: 323-329.
29. de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, et al. (2010) CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 16: 5329-5338.
30. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
31. Spafford MF, Koch WM, Reed AL, Califano JA, Xu LH, et al. (2001) Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res 7: 607-612.
32. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, et al. (2008) Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 14: 97-107.
33. Califano J, Ahrendt SA, Meininger G, Westra WH, Koch WM, et al. (1996) Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res 56: 5720-5722.
34. Allegra E, Garozzo A, Lombardo N, De Clemente M, Carey TE (2006) Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines. Acta Otorinolaryngol Ital 26: 185-190.
35. Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, et al. (2007) Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 16: 102-107.
36. Hoffman RM (2012) ACP Journal Club. Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancermortality. Ann Intern Med 157: JC2-JC4.
37. Chen H, Shu HM, Chang ZL, Wang ZF, Yao HH, et al. (2012) Efficacy of Pap Test in Combination with ThinPrep Cytological Test in Screening for Cervical Cancer. Asian Pac J Cancer Prev 13: 1651-1655.